Ferretti V - Search Results

1

From Physical Mixtures to Co-Crystals: How the Coformers Can Modify Solubility and Biological Activity of Carbamazepine.

Dalpiaz A, Ferretti V, Bertolasi V, Pavan B, Monari A, Pastore M. Dalpiaz A, et al. Among authors: ferretti v. Mol Pharm. 2018 Jan 2;15(1):268-278. doi: 10.1021/acs.molpharmaceut.7b00899. Epub 2017 Dec 6. Mol Pharm. 2018. PMID: 29164899

2

Indomethacin co-crystals and their parent mixtures: does the intestinal barrier recognize them differently?

Ferretti V, Dalpiaz A, Bertolasi V, Ferraro L, Beggiato S, Spizzo F, Spisni E, Pavan B. Ferretti V, et al. Mol Pharm. 2015 May 4;12(5):1501-11. doi: 10.1021/mp500826y. Epub 2015 Apr 1. Mol Pharm. 2015. PMID: 25794305

3

Can pharmaceutical co-crystals provide an opportunity to modify the biological properties of drugs?

Dalpiaz A, Pavan B, Ferretti V. Dalpiaz A, et al. Among authors: ferretti v. Drug Discov Today. 2017 Aug;22(8):1134-1138. doi: 10.1016/j.drudis.2017.01.010. Epub 2017 Jan 24. Drug Discov Today. 2017. PMID: 28130117

4

Supramolecular hydrogen-bonding patterns of co-crystals containing the active pharmaceutical ingredient (API) phloroglucinol and N-heterocycles.

Cvetkovski A, Bertolasi V, Ferretti V. Cvetkovski A, et al. Among authors: ferretti v. Acta Crystallogr B Struct Sci Cryst Eng Mater. 2016 Jun 1;72(Pt 3):326-34. doi: 10.1107/S2052520616004406. Epub 2016 May 13. Acta Crystallogr B Struct Sci Cryst Eng Mater. 2016. PMID: 27240764

5

Drug Release from Pharmaceutical Co-Crystals: Are Therapeutic and Safety Properties of Active Pharmaceutical Substances Retained?

Dalpiaz A, Ferretti V, Botti G, Pavan B. Dalpiaz A, et al. Among authors: ferretti v. Curr Drug Deliv. 2019;16(6):486-489. doi: 10.2174/156720181606190723115802. Curr Drug Deliv. 2019. PMID: 31577199

6

New pharmaceutical salts containing pyridoxine.

Cvetkovski A, Ferretti V, Bertolasi V. Cvetkovski A, et al. Among authors: ferretti v. Acta Crystallogr C Struct Chem. 2017 Dec 1;73(Pt 12):1064-1070. doi: 10.1107/S2053229617015765. Epub 2017 Nov 8. Acta Crystallogr C Struct Chem. 2017. PMID: 29206116

7

Covalent versus electrostatic nature of the strong hydrogen bond: discrimination among single, double, and asymmetric single-well hydrogen bonds by variable-temperature X-ray crystallographic methods in beta-diketone enol RAHB systems.

Gilli P, Bertolasi V, Pretto L, Ferretti V, Gilli G. Gilli P, et al. Among authors: ferretti v. J Am Chem Soc. 2004 Mar 31;126(12):3845-55. doi: 10.1021/ja030213z. J Am Chem Soc. 2004. PMID: 15038739

8

A structural study of new potent and selective antagonists to the A2B adenosine receptor.

Ferretti V, Pretto L, Tabrizi MA, Bertolasi V. Ferretti V, et al. Acta Crystallogr B. 2005 Oct;61(Pt 5):569-76. doi: 10.1107/S0108768105021312. Epub 2005 Sep 23. Acta Crystallogr B. 2005. PMID: 16186657

9

Rhenium(V) and technetium(V) nitrido complexes with mixed tridentate π-donor and monodentate π-acceptor ligands.

Boschi A, Cazzola E, Uccelli L, Pasquali M, Ferretti V, Bertolasi V, Duatti A. Boschi A, et al. Among authors: ferretti v. Inorg Chem. 2012 Mar 5;51(5):3130-7. doi: 10.1021/ic202605z. Epub 2012 Feb 10. Inorg Chem. 2012. PMID: 22324784

10

Stereochemistry of serotonin receptor ligands from crystallographic data. Crystal structures of NAN-190.HBr, 1-phenylbiguanide, MDL 72222 and mianserin.HCl and selectivity criteria towards 5-HT1, 5-HT2, and 5-HT3 receptor subtypes.

Dalpiaz A, Ferretti V, Gilli P, Bertolasi V. Dalpiaz A, et al. Among authors: ferretti v. Acta Crystallogr B. 1996 Jun 1;52 ( Pt 3):509-18. doi: 10.1107/s0108768195014765. Acta Crystallogr B. 1996. PMID: 8767764

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

296 results

Search Page

Filters